ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets

Abstract Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trial...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Glenn A. Marsh, Alexander J. McAuley, Gough G. Au, Sarah Riddell, Daniel Layton, Nagendrakumar B. Singanallur, Rachel Layton, Jean Payne, Peter A. Durr, Hannah Bender, Jennifer A. Barr, John Bingham, Victoria Boyd, Sheree Brown, Matthew P. Bruce, Kathie Burkett, Teresa Eastwood, Sarah Edwards, Tamara Gough, Kim Halpin, Jenni Harper, Clare Holmes, William S. J. Horman, Petrus Jansen van Vuren, Suzanne Lowther, Kate Maynard, Kristen D. McAuley, Matthew J. Neave, Timothy Poole, Christina Rootes, Brenton Rowe, Elisha Soldani, Vittoria Stevens, Cameron R. Stewart, Willy W. Suen, Mary Tachedjian, Shawn Todd, Lee Trinidad, Duane Walter, Naomi Watson, Trevor W. Drew, Sarah C. Gilbert, Teresa Lambe, S. S. Vasan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/50b66ce00589424eb554445061a67484
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:50b66ce00589424eb554445061a67484
record_format	dspace
spelling	oai:doaj.org-article:50b66ce00589424eb554445061a674842021-12-02T15:36:30ZChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets10.1038/s41541-021-00315-62059-0105https://doaj.org/article/50b66ce00589424eb554445061a674842021-05-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00315-6https://doaj.org/toc/2059-0105Abstract Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. Groups of ferrets received either prime-only or prime-boost administration of ChAdOx1 nCoV-19 via the intramuscular or intranasal route. All ChAdOx1 nCoV-19 administration combinations resulted in significant reductions in viral loads in nasal-wash and oral swab samples. No vaccine-associated adverse events were observed associated with the ChAdOx1 nCoV-19 candidate, with the data from this study suggesting it could be an effective and safe vaccine against COVID-19. Our study also indicates the potential for intranasal administration as a way to further improve the efficacy of this leading vaccine candidate.Glenn A. MarshAlexander J. McAuleyGough G. AuSarah RiddellDaniel LaytonNagendrakumar B. SinganallurRachel LaytonJean PaynePeter A. DurrHannah BenderJennifer A. BarrJohn BinghamVictoria BoydSheree BrownMatthew P. BruceKathie BurkettTeresa EastwoodSarah EdwardsTamara GoughKim HalpinJenni HarperClare HolmesWilliam S. J. HormanPetrus Jansen van VurenSuzanne LowtherKate MaynardKristen D. McAuleyMatthew J. NeaveTimothy PooleChristina RootesBrenton RoweElisha SoldaniVittoria StevensCameron R. StewartWilly W. SuenMary TachedjianShawn ToddLee TrinidadDuane WalterNaomi WatsonTrevor W. DrewSarah C. GilbertTeresa LambeS. S. VasanNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Glenn A. Marsh Alexander J. McAuley Gough G. Au Sarah Riddell Daniel Layton Nagendrakumar B. Singanallur Rachel Layton Jean Payne Peter A. Durr Hannah Bender Jennifer A. Barr John Bingham Victoria Boyd Sheree Brown Matthew P. Bruce Kathie Burkett Teresa Eastwood Sarah Edwards Tamara Gough Kim Halpin Jenni Harper Clare Holmes William S. J. Horman Petrus Jansen van Vuren Suzanne Lowther Kate Maynard Kristen D. McAuley Matthew J. Neave Timothy Poole Christina Rootes Brenton Rowe Elisha Soldani Vittoria Stevens Cameron R. Stewart Willy W. Suen Mary Tachedjian Shawn Todd Lee Trinidad Duane Walter Naomi Watson Trevor W. Drew Sarah C. Gilbert Teresa Lambe S. S. Vasan ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
description	Abstract Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. Groups of ferrets received either prime-only or prime-boost administration of ChAdOx1 nCoV-19 via the intramuscular or intranasal route. All ChAdOx1 nCoV-19 administration combinations resulted in significant reductions in viral loads in nasal-wash and oral swab samples. No vaccine-associated adverse events were observed associated with the ChAdOx1 nCoV-19 candidate, with the data from this study suggesting it could be an effective and safe vaccine against COVID-19. Our study also indicates the potential for intranasal administration as a way to further improve the efficacy of this leading vaccine candidate.
format	article
author	Glenn A. Marsh Alexander J. McAuley Gough G. Au Sarah Riddell Daniel Layton Nagendrakumar B. Singanallur Rachel Layton Jean Payne Peter A. Durr Hannah Bender Jennifer A. Barr John Bingham Victoria Boyd Sheree Brown Matthew P. Bruce Kathie Burkett Teresa Eastwood Sarah Edwards Tamara Gough Kim Halpin Jenni Harper Clare Holmes William S. J. Horman Petrus Jansen van Vuren Suzanne Lowther Kate Maynard Kristen D. McAuley Matthew J. Neave Timothy Poole Christina Rootes Brenton Rowe Elisha Soldani Vittoria Stevens Cameron R. Stewart Willy W. Suen Mary Tachedjian Shawn Todd Lee Trinidad Duane Walter Naomi Watson Trevor W. Drew Sarah C. Gilbert Teresa Lambe S. S. Vasan
author_facet	Glenn A. Marsh Alexander J. McAuley Gough G. Au Sarah Riddell Daniel Layton Nagendrakumar B. Singanallur Rachel Layton Jean Payne Peter A. Durr Hannah Bender Jennifer A. Barr John Bingham Victoria Boyd Sheree Brown Matthew P. Bruce Kathie Burkett Teresa Eastwood Sarah Edwards Tamara Gough Kim Halpin Jenni Harper Clare Holmes William S. J. Horman Petrus Jansen van Vuren Suzanne Lowther Kate Maynard Kristen D. McAuley Matthew J. Neave Timothy Poole Christina Rootes Brenton Rowe Elisha Soldani Vittoria Stevens Cameron R. Stewart Willy W. Suen Mary Tachedjian Shawn Todd Lee Trinidad Duane Walter Naomi Watson Trevor W. Drew Sarah C. Gilbert Teresa Lambe S. S. Vasan
author_sort	Glenn A. Marsh
title	ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
title_short	ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
title_full	ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
title_fullStr	ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
title_full_unstemmed	ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
title_sort	chadox1 ncov-19 (azd1222) vaccine candidate significantly reduces sars-cov-2 shedding in ferrets
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/50b66ce00589424eb554445061a67484
work_keys_str_mv	AT glennamarsh chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT alexanderjmcauley chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT goughgau chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT sarahriddell chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT daniellayton chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT nagendrakumarbsinganallur chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT rachellayton chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT jeanpayne chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT peteradurr chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT hannahbender chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT jenniferabarr chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT johnbingham chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT victoriaboyd chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT shereebrown chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT matthewpbruce chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT kathieburkett chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT teresaeastwood chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT sarahedwards chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT tamaragough chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT kimhalpin chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT jenniharper chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT clareholmes chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT williamsjhorman chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT petrusjansenvanvuren chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT suzannelowther chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT katemaynard chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT kristendmcauley chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT matthewjneave chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT timothypoole chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT christinarootes chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT brentonrowe chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT elishasoldani chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT vittoriastevens chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT cameronrstewart chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT willywsuen chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT marytachedjian chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT shawntodd chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT leetrinidad chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT duanewalter chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT naomiwatson chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT trevorwdrew chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT sarahcgilbert chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT teresalambe chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets AT ssvasan chadox1ncov19azd1222vaccinecandidatesignificantlyreducessarscov2sheddinginferrets
_version_	1718386288078356480

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets

Ejemplares similares